{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T20:38:19Z","timestamp":1776112699029,"version":"3.50.1"},"reference-count":5,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1097\/wno.0000000000002023","type":"journal-article","created":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T18:08:27Z","timestamp":1701194907000},"page":"e575-e577","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Clinically Aggressive Low-Grade Optic Nerve Glioma in an Adult Treated With Selumetinib"],"prefix":"10.1097","volume":"44","author":[{"given":"Alexis S.","family":"Kassotis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria D. L.","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joyce N.","family":"Mbekeani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Kazim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2023,11,27]]},"reference":[{"key":"R1-20250526","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1097\/ICU.0000000000000587","article-title":"Current treatment of optic nerve gliomas","volume":"30","author":"Farazdaghi","year":"2019","journal-title":"Curr Opin Ophthalmol."},{"key":"R2-20250526","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1001\/jamaophthalmol.2019.4511","article-title":"SETD2 mutation in an aggressive optic nerve glioma","volume":"138","author":"Campbell","year":"2020","journal-title":"JAMA Ophthalmol."},{"key":"R3-20250526","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1200\/JCO.2014.58.3922","article-title":"BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma","volume":"33","author":"Mistry","year":"2015","journal-title":"J Clin Oncol."},{"key":"R4-20250526","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1186\/s12885-018-5120-0","article-title":"BRAF V600E mutation and 9p21: CDKN2A\/B and MTAP co-deletions\u2014markers in the clinical stratification of pediatric gliomas","volume":"18","author":"Fraz\u00e3o","year":"2018","journal-title":"BMC Cancer"},{"key":"R5-20250526","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.3390\/ijms20112658","article-title":"Detection and correlation of single and concomitant TP53, PTEN, and CDKN2A alterations in gliomas","volume":"20","author":"Pess\u00f4a","year":"2019","journal-title":"Int J Mol Sci."}],"container-title":["Journal of Neuro-Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/WNO.0000000000002023","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T18:03:31Z","timestamp":1748282611000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/WNO.0000000000002023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,27]]},"references-count":5,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/wno.0000000000002023","relation":{},"ISSN":["1070-8022","1536-5166"],"issn-type":[{"value":"1070-8022","type":"print"},{"value":"1536-5166","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,27]]}}}